Scarica l'app Stockscreener
38.02
2.34%
-0.91
Dopo l'orario di chiusura:
37.32
-0.70
-1.84%
Precedente Chiudi:
$38.93
Aprire:
$39.1
Volume 24 ore:
1.94M
Relative Volume:
1.36
Capitalizzazione di mercato:
$3.68B
Reddito:
$7.50M
Utile/perdita netta:
$-383.17M
Rapporto P/E:
-8.0811
EPS:
-4.7048
Flusso di cassa netto:
$-307.84M
1 W Prestazione:
+2.92%
1M Prestazione:
-36.80%
6M Prestazione:
-33.12%
1 anno Prestazione:
-3.01%
Intervallo 1D:
$37.26
$39.10
Intervallo di 1 settimana:
$36.10
$39.92
Portata 52W:
$36.07
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.02 | 3.58B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Why is Xenon Pharmaceuticals stock rallying today? - Investing.com India
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - TradingView
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - marketscreener.com
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
Xenon Pharmaceuticals President & CEO Purchased Shares Worth Over $1.1M - TradingView
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Ian Mortimer Receives the 2026 Bloom Burton Award - Nasdaq
Defence Therapeutics appoints Sherry Aulin to B... - Pluang
Jefferies cuts Xenon Pharmaceuticals stock price target on trial pause By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & HeadlinesYahoo Finance - ca.finance.yahoo.com
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance UK
XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) For Potential Securities Fraud - ACCESS Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Xenon Pharmaceuticals Inc. (XENE) - ACCESS Newswire
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Insider Monkey
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - Block Island Times
Xenon Pharmaceuticals stock falls 30.69 percent as trial pause hits - AD HOC NEWS
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures - NeurologyLive
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Craters 30%: Reading the Charts After the Depression Trial Pause - MEXC
Company News for Sep 21, 2026 - Yahoo Finance
Xenon shares slide more than 30% as company pauses psychiatry trial enrollment - thepharmaletter.com
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - TIKR.com
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why - webull.com
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST) - The Globe and Mail
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
XENE Stock Drops 30% on Phase 3 Trial Halt; Price-to-Sales Ratio Signals Market Skepticism - GuruFocus
Xenon Halts Enrollment in Depression Trials After Psychosis Reports - finance.biggo.com
Xenon downgraded at Deutsche Bank on trial pause (XENE:NASDAQ) - Seeking Alpha
Xenon stock plunges as B.C. drug developer pauses enrolment in depression study - The Globe and Mail
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade) (NASDAQ:XENE) - Seeking Alpha
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge - Benzinga
Xenon: FOS read-across in MDD, BD hitches with Kv7? - BioWorld News
Xenon Pharmaceuticals Faces Setback Amid Clinical Study Pause - GuruFocus
XENE Maintains Outperform Rating -- Price Target Lowered to $70 - GuruFocus
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Sep 30 '26 |
Buy |
37.38 |
30,000 |
1,121,400 |
49,923 |
| Svoronos Dawn | Director |
Sep 01 '26 |
Option Exercise |
8.15 |
5,144 |
41,924 |
31,373 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Aug 28 '26 |
Sale |
60.25 |
7,068 |
425,829 |
2 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):